AIMS: To assess the effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem. METHODS: In a randomized cross-over study with two phases, 10 healthy subjects ingested 10 mg ofzolpidem with or without oral voriconazole pretreatment. The concentrations of zolpidem were measured in plasma up to 24 h and pharmacodynamic variables were monitored for 12 h. RESULTS:Voriconazole increased the peak plasma concentration of zolpidem by 1.23-fold [P < 0.05; 90% confidence interval (CI) 1.05, 1.45] and the area under the plasma zolpidem concentration-time curve by 1.48-fold (P < 0.001; 90% CI 1.29, 1.74). The time to peak plasma zolpidem concentration was unchanged by voriconazole but the half-life was prolonged from 3.2 to 4.1 h (P < 0.01; 95% CI on the difference 0.27, 1.45). The pharmacodynamics of zolpidem were unaffected by voriconazole. CONCLUSION:Voriconazole caused a moderate increase in exposure to zolpidem in healthy young subjects but no clear pharmacodynamic changes were observed between the groups.
RCT Entities:
AIMS: To assess the effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem. METHODS: In a randomized cross-over study with two phases, 10 healthy subjects ingested 10 mg of zolpidem with or without oral voriconazole pretreatment. The concentrations of zolpidem were measured in plasma up to 24 h and pharmacodynamic variables were monitored for 12 h. RESULTS:Voriconazole increased the peak plasma concentration of zolpidem by 1.23-fold [P < 0.05; 90% confidence interval (CI) 1.05, 1.45] and the area under the plasma zolpidem concentration-time curve by 1.48-fold (P < 0.001; 90% CI 1.29, 1.74). The time to peak plasma zolpidem concentration was unchanged by voriconazole but the half-life was prolonged from 3.2 to 4.1 h (P < 0.01; 95% CI on the difference 0.27, 1.45). The pharmacodynamics of zolpidem were unaffected by voriconazole. CONCLUSION:Voriconazole caused a moderate increase in exposure to zolpidem in healthy young subjects but no clear pharmacodynamic changes were observed between the groups.
Authors: D J Greenblatt; L L von Moltke; J S Harmatz; A L Durol; J P Daily; J A Graf; P Mertzanis; J L Hoffman; R I Shader Journal: J Acquir Immune Defic Syndr Date: 2000-06-01 Impact factor: 3.731
Authors: Teijo I Saari; Kari Laine; Kari Leino; Mika Valtonen; Pertti J Neuvonen; Klaus T Olkkola Journal: Clin Pharmacol Ther Date: 2006-04 Impact factor: 6.875
Authors: Joel O Olubodun; Hermann R Ochs; Lisa L von Moltke; Ronenn Roubenoff; Leah M Hesse; Jerold S Harmatz; Richard I Shader; David J Greenblatt Journal: Br J Clin Pharmacol Date: 2003-09 Impact factor: 4.335
Authors: Nora M Hagelberg; Tuija H Nieminen; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola Journal: Eur J Clin Pharmacol Date: 2008-10-03 Impact factor: 2.953
Authors: Mari Fihlman; Tuija Hemmilä; Nora M Hagelberg; Kristiina Kuusniemi; Janne T Backman; Jouko Laitila; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola; Teijo I Saari Journal: Eur J Clin Pharmacol Date: 2016-08-10 Impact factor: 2.953